

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JW (Cayman) Therapeutics Co. Ltd**

**藥明巨諾（開曼）有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2126)**

**VOLUNTARY ANNOUNCEMENT  
POTENTIAL FURTHER STRATEGIC PARTNERSHIP  
WITH 2SEVENTY BIO, INC.**

JW (Cayman) Therapeutics Co. Ltd (the “**Company**” or “**JW Therapeutics**”) is pleased to announce its intention to expand its strategic alliance (the “**Potential Collaboration**”) with 2seventy bio, Inc (“**2seventy bio**”).

The Potential Collaboration, based on the partnership that the Company established with 2seventy bio in 2022, builds upon the Company and 2seventy bio’s translational and clinical cell therapy development platform originally designed to more rapidly explore T cell-based immunotherapy products in Greater China. Specifically, the Company and 2seventy bio intend to co-develop further candidates from the portfolio of 2seventy bio, targeting solid tumor indications using T-cell receptor based technology and autoimmune diseases using a CAR-T cell approach.

As of the date of this announcement, the Potential Collaboration is still under negotiations and no definitive agreement has been entered into by the Company and 2seventy bio in respect of the Potential Collaboration. Therefore, the Potential Collaboration may or may not proceed. Should the Potential Collaboration materializes, it may constitute a notifiable transaction under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The Company will make further announcements in compliance with the Listing Rules as and when appropriate.

## About JW Therapeutics

JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit [www.jwtherapeutics.com](http://www.jwtherapeutics.com).

## About 2seventy bio

2seventy bio is a cell and gene therapy company which is engaged in the research, development, and commercialization of transformative treatments for cancer, with a goal to truly disrupt the cancer treatment landscape. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, next generation targeted cellular therapies for patients with cancer. 2seventy bio's lead product, ABECMA, is the first CAR T cell therapy approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma. For more information, please visit [www.2seventybio.com](http://www.2seventybio.com).

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market cell therapy products contemplated under the Potential Collaboration successfully. The shareholders of the Company and investors are urged to exercise caution when dealings in the securities of the Company. Further announcements in respect of the Potential Collaboration will be made by the Company in the event any legally binding agreement has been signed.**

By order of the Board  
JW (Cayman) Therapeutics Co. Ltd  
藥明巨諾(開曼)有限公司\*  
Yiping James Li  
Chairman

Shanghai, PRC, September 12, 2023

*As of the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive director, Ms. Xing Gao, Dr. Sungwon Song and Dr. Cheng Liu as non-executive directors, and Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu, Dr. Krishnan Viswanadhan and Dr. Ann Li Lee as independent non-executive directors.*

\* For identification purposes only